Immunocore Holdings plc American Depositary Shares
IMCRStock
$34.47−1.34%52W
Market Cap$1.76B
P/E—
Div yield—
Beta0.74
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-6.73%
Price vs S&P 500 (4W)22.51%
VGM Score58.18
Market Capitalization$1.76B
Earnings Surprise History
Q1 260.25est. -0.26
Analyst Recommendations
Apr 2026
May 2026
Jun 2026
Jul 2026
4.09
4.09
4.09
4.09
Industry Peers — Biological Products(180)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
IMCRImmunocore Holdings plc American Depositary Shares | D | B | B | $34.47 |
| AMGNAmgen Inc | C | C | C | $371.58 |
| GILDGilead Sciences Inc | C | B | C | $136.30 |
| ARGXargenx SE American Depositary Shares | D | A | B | $857.97 |
| RVMDRevolution Medicines, Inc. Common Stock | F | — | A | $179.18 |
| BIIBBiogen Inc. Common Stock | B | D | B | $208.92 |
| BNTXBioNTech SE American Depositary Share | C | C | C | $91.56 |
| MRNAModerna, Inc. Common Stock | D | B | B | $63.15 |
| NBIXNeurocrine Biosciences Inc | C | B | B | $171.55 |
| EXELExelixis Inc | C | B | B | $55.68 |
| TECHBio-Techne Corp. | D | C | B | $71.77 |
About
Immunocore is a commercial-stage biotechnology company that markets KIMMTRAK for unresectable and metastatic uveal melanoma. The company leverages its proprietary ImmTAX platform to develop a pipeline of candidates across oncology, infectious disease, and autoimmune disorders, including Brenetafusp and other clinical and pre-clinical programs.